Aspergillosis clinical trials

The registry lists 134 studies for Aspergillosis across more than 10 countries. 10 are recruiting or about to start. 99 of them are mainly about Aspergillosis (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-01. Counting its 3 narrower conditions too, such as Invasive Pulmonary Aspergillosis: 222 studies, 34 open.

Get an email when these change. Save the Aspergillosis studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 85
Terminated: 15
Status unknown: 13
Recruiting: 8
Withdrawn: 7
Active, not recruiting: 3

Phase

Phase 2: 28
Phase 3: 26
Phase 1: 18
Phase 4: 10

Where

United States: 28
Germany: 21
United Kingdom: 20
France: 19
Belgium: 14
Netherlands: 12

Who runs them

F2G Biotech GmbH (11) · Pfizer (11) · Merck Sharp & Dohme LLC (10) · Heidelberg University (7) · Astellas Pharma Inc (6) · National Cancer Institute (NCI) (5) · Post Graduate Institute of Medical Education and Research, Chandigarh (4) · Astellas Pharma China, Inc. (3)

What is being tested here

Drugs under test in Aspergillosis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Posaconazole	1	4	6
Fluconazole	1	1	2
Voriconazole	0	5	15
Micafungin	0	1	8
Amphotericin B	0	2	6
Caspofungin	0	0	5
Anidulafungin	0	3	5
Itraconazole	0	1	4
Isavuconazole	0	3	3
Opelconazole	0	0	3

Coming up

1phase 3 study under way

2studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 2

Nov 2026Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study · Manchester University NHS Foundation Trust
Nov 2027PTX3-targeted Antifungal Prophylaxis · Bochud Pierre-Yves

Who these studies take

Of the 8 Aspergillosis studies recruiting now, 6 (75%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (13%) take healthy volunteers.

Recruiting studies that take each age, of 8
Age	Women	Men
10	0 (0%)	0 (0%)
18	5 (63%)	5 (63%)
30	7 (88%)	7 (88%)
40	7 (88%)	7 (88%)
50	7 (88%)	7 (88%)
65	8 (100%)	8 (100%)
75	8 (100%)	8 (100%)
85	7 (88%)	7 (88%)

Across all 134 studies, recruiting or not: 23% stop at 75 or younger and 22% at 65; 40% take children; 0% are for women only and 4% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Aspergillosis studies take

Of 19 observational studies under Aspergillosis, half reached primary completion within 45 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Observational	45 mo11–56 · 19 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 134. Browse all 134 → or search them.